Results 41 to 50 of about 105,726 (291)

The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function

Transplantation Direct, 2023
Background. Calcineurin inhibitors are inherent vasoconstrictors. Cerebral vasoconstriction can reduce cerebral blood flow (CBF), and negatively impact cerebrovascular response (CVR) to exercise, and cognitive function.
Irisa Mahaparn, MD, Rebecca J. Lepping, PhD, Robert N. Montgomery, PhD, Rishav Mukherjee, MSc, Sandra A. Billinger, PhD, William M. Brooks, PhD, Aditi Gupta, MD   +6 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation–associated protein 5 (MDA5) antibody–associated dermatomyositis (DM). Methods Thirty patients with MDA5 antibody–associated DM were identified in a single‐center longitudinal cohort of 352
Jenice X. Cheah, Sangmee S. Bae, Tiffany De Leon, Yuna Lee, Rong Guo, David Elashoff, Jennifer Wang, Ani Shahbazian, Christina Charles‐Schoeman   +8 more
wiley   +1 more source

Tacrolimus intrapatient variability and latent virus reactivation after kidney transplantation: A retrospective study comparing prolonged-release and immediate-release tacrolimus formulations

Journal of International Medical Research
Objective This study explored the differences in intrapatient variability of tacrolimus between prolonged-release and immediate-release formulations and evaluated the association between tacrolimus intrapatient variability and reactivation of BK virus ...
Sibel Ersan, Gulin Kavakalan, Gursel Ersan, Gozde Buhur Sari, Sibel Akkurt, Mehmet Tanrisev   +5 more
doaj   +1 more source

Tacrolimus for the Treatment of Ulcerative Colitis [PDF]

Intestinal Research, 2015
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients ...
Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe   +7 more
doaj   +1 more source

An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.

Kidney International, 2019
This is a randomized trial (ATHENA study) in de novo kidney transplant patients to compare everolimus versus mycophenolic acid (MPA) with similar tacrolimus exposure in both groups, or everolimus with concomitant tacrolimus or cyclosporine (CsA), in an ...
C. Sommerer, B. Suwelack, D. Dragun, P. Schenker, I. Hauser, O. Witzke, C. Hugo, N. Kamar, P. Merville, M. Junge, F. Thaiss, B. Nashan   +11 more
semanticscholar   +1 more source

Prevalence of Systemic Lupus Erythematosus in Australia, 2010–2022: A Population‐Based Study Using Linked National Administrative Health Data

Arthritis Care &Research, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper, Rachel Black, Joanna Tieu, Winnie Chen, Matthew Parker, Catherine Hill, Natasha Nassar, Mandana Nikpour   +7 more
wiley   +1 more source

Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report

Journal of Medical Case Reports
Background Tacrolimus is a potent calcineurin inhibitor (CNI) that is principally used as a first-line immunosuppressant for the prophylaxis of allograft rejection in liver transplantation (LT) patients.
Vichapat Tharanon, Pansa Iamrahong, Jutamas Tuamsem, Kunvadee Choochaeam, Titinun Auamnoy, Abhasnee Sobhonslidsuk   +5 more
doaj   +1 more source

Improved kidney function and one-year survival with transitioning from intravenous to enteral tacrolimus in lung transplant recipients

Transplantation Reports
Background: Acute kidney injury (AKI) is common after lung transplant and may increase risk of chronic kidney disease (CKD). Calcineurin inhibitors (CNIs) such as tacrolimus contribute to AKI risk.
Carrie Burt, Georgina Waldman, Linda Awdishu, Kamyar Afshar, Mark Mariski, Jade Kozuch, Gordon Yung, Eugene Golts, Ashley Feist   +8 more
doaj   +1 more source

The level of intracellular tacrolimus in T cell is affected by CD44 ABCB1 activities triggered by inflammation

European Journal of Inflammation, 2019
Rejection is an important issue in kidney transplant. Although with adequate trough level of tacrolimus, acute rejection occurs, and we are focused on these cases.
Eunjin Bae, Seung Seok Han, Dong Jun Park, Hajeong Lee, Mi-Yeon Yu, Kyu Hong Kim, Min Chang Kim, Joo-Youn Cho, Sang-Il Min, Jongwon Ha, Yon Su Kim, Seung Hee Yang   +11 more
doaj   +1 more source